MetaCap

Amphastar Pharmaceuticals (AMPH) vs Silence Therapeutics Plc American Depository Share (SLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Silence Therapeutics Plc American Depository Share (SLN) has outperformed Amphastar Pharmaceuticals (AMPH) over the past year, gaining 213.9% versus a gain of 8.6%. Over five years, AMPH leads with a +41.9% price change compared with -10.0% for SLN. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($1.23 billion vs $1.20 billion), about 1.0 times the size, while Amphastar Pharmaceuticals is growing revenue faster (-1.7% vs -98.7%).

Amphastar Pharmaceuticals converts more of its revenue into profit, with a net margin of 13.6% versus -15851.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMPH+8.61%SLN+213.95%
+227%+90%-48%
Nov 21, 20251 yearNov 20, 2026
AMPH+37.74%SLN-13.68%
+221%+59%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMPH versus SLN key metrics
MetricAMPHSLN
Share price$28.25$19.81
Market cap$1.20B$1.23B
1-day change+0.50%0.00%
YTD return+5.49%+225.82%
1-year return+8.61%+213.95%
5-year return+41.89%-9.95%
P/E ratio (TTM)12.96—
Forward P/E8.43—
EPS (TTM)$2.18$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$719.89M$559.00K
Revenue growth (YoY)-1.65%-98.71%
Net income (latest FY)$98.09M$-88.61M
Gross margin49.46%61.54%
Operating margin19.50%-16292.84%
Net margin13.63%-15851.88%
52-week high$31.00$19.87
52-week low$16.65$4.19
Distance from 52-week high-8.87%-0.28%
Analyst consensusholdhold
Avg. price target upside-13.27%-0.30%
Average volume475.35K2.41M
Shares outstanding42.65M62.20M
Employees1,97688
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLN has outperformed AMPH by 205.3 percentage points over the past year.
  • Amphastar Pharmaceuticals is more profitable, keeping 13.6 cents of every revenue dollar as net income versus -15851.9 cents for Silence Therapeutics Plc American Depository Share.
  • Amphastar Pharmaceuticals grew revenue faster in its latest fiscal year (-1.65% vs -98.71%).

About Amphastar Pharmaceuticals

AMPH stock →

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees

About Silence Therapeutics Plc American Depository Share

SLN stock →

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees

AMPH vs SLN FAQ

Which is bigger, Amphastar Pharmaceuticals or Silence Therapeutics Plc American Depository Share?

Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $1.23B compared with $1.20B for Amphastar Pharmaceuticals (AMPH).

Which stock has performed better over the past year, AMPH or SLN?

SLN returned +213.95% over the past 12 months, compared with +8.61% for AMPH (price return, excluding dividends). Past performance does not predict future results.

Are Amphastar Pharmaceuticals and Silence Therapeutics Plc American Depository Share in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons